#United States #Philadelphia #FDA #Clinical Trials #TransCelerate

TransCelerate and FDA Collaboration: A New Era in Clinical Trials

TransCelerate BioPharma, a nonprofit organization devoted to enhancing global health, has announced a significant collaboration with the U.S. Food and Drug Administration (FDA) to refine the process of safety data collection in clinical trials. This partnership aims to ensure that clinical research not only gathers essential data but also prepares for practical applications that better reflect real-world practices.

New Report Highlights Practical Strategies for Trials

On May 5, 2026, TransCelerate released an insightful report summarizing the results of a recent tabletop exercise conducted alongside the FDA's Center for Drug Evaluation and Research (CDER) and the Center for Clinical Trial Innovation (C3TI). This report emphasizes the role of selective safety data collection (SSDC) in streamlining data gathering processes essential for integrating pragmatic elements into clinical trials.

The SSDC approach is pivotal; it is informed by guidelines from the International Council for Harmonization (ICH) and new regulatory frameworks, including an FDA white paper that acknowledges its potential in clinical research. By adopting a risk-based methodology, SSDC allows trials to be designed with safety and data integrity as paramount concerns.

Engendering Productive Dialogue

The informal exercise held in late 2025 brought together over 20 leaders in pharmaceutical research and development from TransCelerate and more than 15 FDA representatives. The collaborative event built upon earlier discussions that aimed to enhance understanding between regulatory bodies and sponsors, particularly regarding safety reporting.

Rob DiCicco, Vice President of Portfolio Management at TransCelerate, stated, “Our ongoing collaboration with the FDA is directed toward exploring real-world clinical trial scenarios, sharing these findings, and building confidence among sponsors to incorporate pragmatic elements into their studies.” This partnership aims to enhance transparency and facilitate effective communication across all stakeholders in the research and development sector.

Structured Discussions Shape Future Trials

During the recent exercise, representatives from the FDA and TransCelerate engaged in systematic discussions based on hypothetical trial scenarios developed across key therapeutic areas, including obesity, cardiovascular health, pulmonology, and dermatology. These scenarios were instrumental in analyzing the practical integration of SSDC approaches within trial design, operational execution, and oversight processes.

Kevin Bugin, Head of Global Regulatory Policy at Amgen and a key figure in TransCelerate’s Embedded Pragmatic Trials initiative, emphasized the importance of these discussions for fostering a collaborative environment in clinical research. “We foresee growing interest from other health authorities to participate in similar discussions,” he noted, suggesting a ripple effect that could enhance pragmatic approaches in trials worldwide.

Conclusion

The public summary of the tabletop exercise is now available, marking a milestone in the collaboration between TransCelerate and the FDA aimed at modernizing clinical trials through more effective and practical methodologies. For more insights on TransCelerate’s Embedded Pragmatic Trials initiative, interested parties can visit their official site.

TransCelerate continues to lead with innovative approaches that not only aim to accelerate clinical research but also prioritize patient safety and real-world application. As they progress, this collaboration sets a benchmark for future partnerships between regulatory agencies and biopharmaceutical companies, driving faster and safer dissemination of new treatments to those in need.